T2N1M0 Non-Small Cell Lung Cancer: Surgery and Prognostic Factors

Padilla, J.; Calvo, V.; Peñalver, J.C.; Jordá, C.; Escrivá, J.; Cerón, J.; Zarza, A. García; Pastor, J.; Blasco, E.

doi:10.1016/S1579-2129(06)60258-9

Archivos de Bronconeumología

ISSN: 0300-2896

Archivos de Bronconeumologia is a scientific journal that preferentially publishes prospective original research articles whose content is based upon results dealing with several aspects of respiratory diseases such as epidemiology, pathophysiology, clinics, surgery, and basic investigation. Other types of articles such as reviews, editorials, a few special articles of interest to the society and the editorial board, scientific letters, letters to the Editor, and clinical images are also published in the Journal. It is a monthly Journal that publishes a total of 12 issues and a few supplements, which contain articles belonging to the different sections.

All the manuscripts received in the Journal are evaluated by the Editors and sent to expert peer-review while handled by the Editor and/or an Associate Editor from the team. The Journal is published monthly in English.

Manuscripts will be submitted electronically using the following web site: https://www.editorialmanager.com/ARBR/, link which is also accessible through the main web page of Archivos de Bronconeumologia.

Access to any published article, is possible through the Journal's web page as well as from PubMed, Science Direct, and other international databases. Furthermore, the Journal is also present in Twitter and Facebook. The Journal expresses the voice of the Spanish Respiratory Society of Pulmonology and Thoracic Surgery (SEPAR) as well as that of other scientific societies such as the Latin American Thoracic Society (ALAT) and the Iberian American Association of Thoracic Surgery (AICT).

Authors are also welcome to submit their articles to the Journal's open access companion title, Open Respiratory Archives.

Archivos de Bronconeumologia has received the new Impact Factor (JCR). The impact factor has risen from 6.333 in 2021 to 8 in the last evaluated year, 2022.
It is needed to be a member of SEPAR or have a subscription to access full texts of articles published last year. Abstracts are available for all visitors.

Indexed in:

Current Contents/Clinical Medicine, JCR SCI-Expanded, Index Medicus/Medline, Excerpta Medica/EMBASE, IBECS, IME, SCOPUS, IBECS

Subscribe:

Impact factor

The Impact Factor measures the average number of citations received in a particular year by papers published in the journal during the two preceding years.

© Clarivate Analytics, Journal Citation Reports 2022

Impact factor 2022

Citescore

CiteScore measures average citations received per document published.

Citescore 2022

2.8

SJR

SRJ is a prestige metric based on the idea that not all citations are the same. SJR uses a similar algorithm as the Google page rank; it provides a quantitative and qualitative measure of the journal's impact.

SJR 2022

0.434

SNIP

SNIP measures contextual citation impact by wighting citations based on the total number of citations in a subject field.

SNIP 2022

0.437

View more metrics

Open Access Option

Journal Information

Previous article | Next article

Vol. 41. Issue 8.

Pages 430-433 (August 2005)

More article options

Pages 430-433 (August 2005)

Original Articles

DOI: 10.1016/S1579-2129(06)60258-9

Full text access

T2N1M0 Non-Small Cell Lung Cancer: Surgery and Prognostic Factors

Visits

6406

Download PDF

J. Padilla

Corresponding author

jpadilla@comv.es

Correspondence: Dr. J. Padilla. Servicio de Cirugía Torácica. Hospital Universitario La Fe. Avda. de Campanar, 21. 46009 Valencia. España

, V. Calvo, J.C. Peñalver, C. Jordá, J. Escrivá, J. Cerón, A. García Zarza, J. Pastor, E. Blasco

Servicio de Cirugía Torácica, Hospital Universitario La Fe, Valencia, Spain

This item has received

6406 Visits

Article information

Abstract

Bibliography

Download PDF

Statistics

Objective

TO determine the prognostic factors for the survival in a group of patients operated on for a non-small cell lung cancer classified as T2N1M0.

Patients and methods

TWO hundred sixteen patients treated exclusively with surgery were studied. Kaplan-Meier survival and Cox multivariable regression analyses were used.

Results

The overall survival rate was 39.8% at 5 years and 29.9% at 10 years. Sex, age, presence or absence of symptoms, type of resection, and number and location of affected lymph nodes had no effect on survival. Tumor size (P = .04) and histologic type (P = .03) did significantly affect prognosis. Both variables entered into the Cox multivariable regression model.

Conclusions

Patients operated on for non-small cell lung cancer classified as T2N1M0 have an overall probability of 5-year survival of approximately 40%. However, the prognosis for this group of patients is heterogeneous: in our study it was affected by the histologic type (45.5% for squamous cell and 25% for non-squamous cell cancers) and tumor size (53% for tumors with a diameter of ≤3 cm, 45% for tumors between 3.1 and 5 cm, and 29% for a tumor diameter >5 cm).

Key Words:

Carcinoma bronchogenic

Stage IIb

T2N1M0

Surgery

Prognosis

Objetivo

Determinar los factores pronósticos de supervi-vencia de un grupo de pacientes operados de un carcinoma broncogénico no anaplásico de células pequeñas y clasifica-dos como T2N1M0.

Pacientes y métodos

Se estudió a 216 pacientes tratados exclusivamente con cirugía. La supervivencia se analizó con el método de Kaplan-Meier y se utilizó el modelo de Cox para el análisis multivariante.

Resultados

La supervivencia global fue del 39,8% a los 5 años y del 29,9% a los 10 años. El sexo, la edad, la presen-cia o ausencia de síntomas, la amplitud de la exéresis, el nú-mero de ganglios afectados y su localización no influyeron en la supervivencia. El tamaño tumoral (p = 0,04) y la estir-pe histológica (p = 0,03) sí condicionaron significativamente el pronóstico. Ambas variables entraron en regresión cuan-do se utilizó el análisis multivariante.

Conclusiones

Los pacientes operados de un carcinoma broncogénico no anaplásico de células pequeñas clasificado como T2N1M0 tienen una probabilidad de supervivencia global a los 5 años en torno al 40%. Sin embargo, no es un grupo de pacientes con un pronóstico homogéneo, ya que en nuestro estudio estuvo condicionado por la estirpe histológica (un 45,5% para los epidermoides y un 25% para los no epidermoides) y el tamaño tumoral (un 53% en los tumores con un diámetro ≤ 3 cm, un 45% entre 3,1-5 cm y un 29% en > 5 cm).

Palabras clave:

Carcinoma broncogénico

Estadio IIb

T2N1M0

Cirugía

Factores pronósticos

Full text is only aviable in PDF

REFERENCES

[1]

Grupo de Trabajo de la SEPAR.

Normativa actualizada (1998) sobre diagnóstico y estadificación del carcinoma broncogénico.

Arch Bronconeumol, 34 (1998), pp. 437-452

Medline

[2]

N Martini, M Burt, M Bains, P McCormack, V Rusch, R Ginsberg.

Survival after resection of stage II non-small cell lung cancer.

Ann Thorac Surg, 54 (1992), pp. 460-466

Medline

[3]

CF Mountain.

Revision in the international staging system for lung cancer.

Chest, 111 (1997), pp. 1710-1717

Medline

[4]

K Inoue, M Sato, S Fujimura, A Sakurada, S Takahashi, K Usuda, et al.

Prognostic assessment of 1310 patients with non-small-cell lung cancer who underwent complete resection from 1980 to 1993.

J Thorac Cardiovasc Surg, 116 (1998), pp. 407-411

http://dx.doi.org/10.1016/S0022-5223(98)70006-6 | Medline

[5]

T Naruke, R Tsuchiya, H Kondo, H Asamura.

Prognosis and survival after resection for bronchogenic carcinoma based on the 1997 TNM-staging classification: the Japanese experience.

Ann Thorac Surg, 71 (2001), pp. 1759-1764

Medline

[6]

V Calvo Medina, J Padilla Alarcón, F París Romeu, E Blasco Armengod, J Pastor Guillem, A García Zarza.

Supervivencia posquirúrgica en el estadio II del carcinoma broncogénico no anaplásico de células pequeñas.

Arch Bronconeumol, 37 (2001), pp. 19-26

Medline

[7]

E van Velzen, RJ Snijder, A Brutel de la Rivière, HJ Elbers, JM van den Bosch.

Lymph node type as a prognostic factor for survival in T2N1M0 non-small cell lung carcinoma.

Ann Thorac Surg, 63 (1997), pp. 1436-1440

Medline

[8]

T Naruke, K Suemasu, S Ishikawa.

Lymph node mapping and curability at various levels of metastasis in resected lung cancer.

J Thorac Cardiovasc Surg, 76 (1978), pp. 832-839

Medline

[9]

T Yano, H Yokoyama, T Inoue, H Asoh, K Tayama, Y Ichinose.

Surgical results and prognostic factors of pathologic N1 disease in non-small-cell carcinoma.

J Thorac Cardiovasc Surg, 107 (1994), pp. 1398-1402

Medline

[10]

M Riquet, D Manac'h, F le Pimpec-Barthes, A Dujon, A Chehab.

Prognostic significance of surgical-pathologic N1 disease in non-small cell carcinoma of the lung.

Ann Thorac Surg, 67 (1999), pp. 1572-1576

Medline

[11]

A Marra, L Hillejan, G Zaboura, T Fujimoto, D Greschuchna, G Stamatis.

Pathologic N1 non-small cell lung cancer: correlation between pattern of lymphatic spread and prognosis.

J Thorac Cardiovasc Surg, 125 (2003), pp. 543-553

http://dx.doi.org/10.1067/mtc.2003.322 | Medline

[12]

T Osaki, A Nagashima, T Yoshimatsu, Y Tashima, K Yasumoto.

Survival and characteristics of lymph node involvement in patients with N1 non-small cell lung cancer.

Lung Cancer, 43 (2004), pp. 151-157

Medline

[13]

Sayar A, Turna A, Kilicgun A, Solak O, Urer N, Gurses A. Prognostic significance of surgical-pathologic multiple-station N1 disease in non-small cell carcinoma of the lung. Eur J Cardiothorac Surg. 200;25:434-8.

[14]

S Watanabe, G Ladas, P Goldstraw.

Inter-observer variability in systematic nodal dissection: a comparison of European and Japanese nodal designation.

Ann Thorac Surg, 73 (2002), pp. 245-248

Medline

[15]

H Asamura, K Suzuki, H Kondo, R Tsuchiya.

Where is the boundary between N1 and N2 stations in lung cancer?.

Ann Thorac Surg, 70 (2000), pp. 1839-1842

Medline

[16]

PORT Meta-analysis Trialists Group.

Postoperative radiotherapy in non-small-cell lung cancer: systematic review and meta-analysis of individual patient data from nine randomised controlled trials.

Lancet, 352 (1998), pp. 257-263

Medline

[17]

Non-small Cell Lung Cancer Collaborative Group.

Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials.

BMJ, 311 (1995), pp. 899-909

Medline

[18]

The International Adjuvant Lung Cancer Trial Collaborative Group.

Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small-cell lung cancer.

N Engl J Med, 350 (2004), pp. 351-360

http://dx.doi.org/10.1056/NEJMoa031644 | Medline

[19]

KMW Pister, RJ Ginsberg, DJ Giroux, JB Putnam, MG Kriss, DH Johnson, et al.

Induction chemotherapy before surgery for early-stage lung cancer: a novel approach.

J Thorac Cardiovasc Surg, 119 (2000), pp. 423-439

[20]

A Depierre, B Milleron, D Moro-Sibilot, S Chevret, E Quoix, B Lebeau, et al.

Preoperative chemotherapy followed by surgery compared with primary surgery in resectable stage I (except T1N0) II, and IIIa non-small cell lung cancer.

J Clin Oncol, 20 (2002), pp. 247-253

http://dx.doi.org/10.1200/jco.2002.20.1.247 | Medline

Indexed in:

Follow us:

Subscribe:

Subscribe to our newsletter